<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Lee, Randall J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">LAA Ligation with LARIAT Reduces Event Rates in AF</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">Oral anticoagulants (OACs) are effective for preventing embolic events for patients with atrial fibrillation (AF) but are associated with bleeding events. Percutaneous, image-guided, catheter-based ligation can permanently exclude the left atrial appendage (LAA), eliminating the need for OACs and reducing the risk of stroke and embolic events in patients with AF. The catheter-based LARIAT suture delivery device consists of a snare with a pretied suture that is guided over the LAA from an epicardial approach. This article discusses the results of the Lasso Occlusion of the LAA trial [LARIAT] of LAA ligation with the LARIAT device in patients with AF.</style></abstract><number><style face="normal" font="default" size="100%">21</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>